# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Inflation drops, speculations rise on interest rate cuts. Producer inflation data fails to alter expectations, tech sector unde...
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with...
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.
Pfizer announced it will advance development of its once-daily Danuglipron.
Pfizer advances its once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, after positive Pha...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...
Barclays analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $28 to $30.